NCT01001299 is a Phase 1 clinical trial of Drug cocktail in Malignant Melanoma, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT01001299?

NCT01001299 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT01001299?

Interventions in NCT01001299: Drug cocktail, RO5185426.

What condition does NCT01001299 study?

NCT01001299 studies Malignant Melanoma.

Is NCT01001299 still recruiting?

NCT01001299 is currently completed. Last updated 15 August 2017.

Are results published for NCT01001299?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-08-15 · How we verify

NCT01001299

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Completed Phase 1 Results posted Last updated 15 August 2017

What this trial tests

Phase 1 trial testing Drug cocktail in Malignant Melanoma in 25 participants. Completed in 29 February 2012.

Timeline

30 November 2009

Primary endpoint
29 February 2012

29 February 2012

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	30 November 2009
Primary completion	29 February 2012
Estimated completion	29 February 2012
Sites	5 locations across United States

Drugs / interventions tested

Drug cocktail — full drug profile →
RO5185426 — full drug profile →

Conditions studied

Malignant Melanoma — all drugs for Malignant Melanoma →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Malignant Melanoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Geometric Mean Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Observed Sampling Time (AUC[0-last]) of Probe Parent Drugs Primary · Day 1, 20: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

AUC(0-last) was defined as the area under the plasma concentration-time curve calculated using the linear trapezoidal rule from time zero to the last observed sampling time. To assess the potential for drug-drug interactions, the geometric mean ratios and corresponding 90 percent (%) confidence interval (CI) of AUC(0-last) of parent probe drug before (Day 1) and after treatment with vemurafenib (Day 20) was calculated. Ratio and corresponding 90% CI of AUC(0-last) (Day 20/Day 1) for each of the 5 probe drugs is reported.

Caffeine (n = 19)

Group	Value	95% CI
Vemurafenib	2.56	2.24 – 2.93

Dextromethorphan (n = 20)

Group	Value	95% CI
Vemurafenib	1.47	1.21 – 1.78

Midazolam (n = 20)

Group	Value	95% CI
Vemurafenib	0.61	0.50 – 0.74

Omeprazole (n = 20)

Group	Value	95% CI
Vemurafenib	1.13	0.92 – 1.37

S-warfarin (n = 20)

Group	Value	95% CI
Vemurafenib	1.18	1.12 – 1.24

Geometric Mean Ratio of Maximum Plasma Concentration (Cmax) of Probe Parent Drugs Primary · Day 1, 20: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

To assess the potential for drug-drug interactions, the geometric mean ratios and corresponding 90% CI of Cmax of parent probe drug before (Day 1) and after treatment with vemurafenib (Day 20) was calculated. Ratio and corresponding 90% CI of Cmax (Day 20/Day 1) for each of the 5 probe drugs is reported.

Caffeine (n = 19)

Group	Value	95% CI
Vemurafenib	1.05	0.98 – 1.13

Dextromethorphan (n = 20)

Group	Value	95% CI
Vemurafenib	1.36	1.07 – 1.72

Midazolam (n = 20)

Group	Value	95% CI
Vemurafenib	0.65	0.54 – 0.78

Omeprazole (n = 20)

Group	Value	95% CI
Vemurafenib	1.17	0.92 – 1.49

S-warfarin (n = 20)

Group	Value	95% CI
Vemurafenib	1.00	0.93 – 1.08

Geometric Mean Ratio of AUC(0-last) and Cmax of Metabolites of Probe Parent Drugs Primary · Day 1, 20: 0, 1, 3, 4, 6, 8, 24 hours, additionally for paraxanthine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120, dextrorphan 0.5, 1.5, 2, 12, 18, 48, OH-midazolam 0.08, 0.25, 0.5, 0.75, 2, 10, OH-omeprazole 0.5, 1.5, 2, 2.5, 12, 18 hours

AUC(0-last) was defined as the area under the plasma concentration-time curve calculated using the linear trapezoidal rule from time zero to the last observed sampling time. To assess the potential for drug-drug interactions, the geometric mean ratios and corresponding 90% CI of AUC(0-last) and Cmax of metabolites of parent probe drug before (Day 1) and after treatment with vemurafenib (Day 20) was calculated. Ratio and corresponding 90% CI of AUC(0-last) and Cmax (Day 20/Day 1) for each of the 4 probe drug metabolites is reported (paraxanthine \[caffeine metabolite\], dextrorphan \[dextrometh

Paraxanthine - AUC(0-last) (n = 19)

Group	Value	95% CI
Vemurafenib	1.15	0.98 – 1.36

Paraxanthine - Cmax (n = 19)

Group	Value	95% CI
Vemurafenib	0.60	0.53 – 0.68

Dextrorphan - AUC(0-last) (n = 20)

Group	Value	95% CI
Vemurafenib	1.46	1.22 – 1.75

Dextrorphan - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	1.21	0.97 – 1.51

OH-Midazolam - AUC(0-last) (n = 20)

Group	Value	95% CI
Vemurafenib	1.34	1.17 – 1.54

OH-Midazolam - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	1.23	1.04 – 1.44

OH-Omeprazole - AUC(0-last) (n = 20)

Group	Value	95% CI
Vemurafenib	1.16	1.06 – 1.28

OH-Omeprazole - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	1.01	0.87 – 1.18

AUC(0-last) and Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Probe Parent Drugs and Their Metabolites on Day 1 Primary · Day 1: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

AUC(0-last) was defined as the area under the plasma concentration-time curve calculated using the linear trapezoidal rule from time zero to the last observed sampling time. AUC(0-inf) was defined as the area under the plasma concentration-time curve calculated using the linear trapezoidal rule from time zero extrapolated to infinity. Timeframe reported for parent probe drug is also applicable for their metabolite except S-warfarin, as S-warfarin does not have a metabolite.

Caffeine - AUC(0-last) (n = 19)

Group	Value	95% CI
Vemurafenib	56350.1	± 24744.07

Caffeine - AUC(0-inf) (n = 19)

Group	Value	95% CI
Vemurafenib	58337.5	± 25287.72

Paraxanthine - AUC(0-last) (n = 19)

Group	Value	95% CI
Vemurafenib	45584.3	± 15667.21

Paraxanthine - AUC(0-inf) (n = 19)

Group	Value	95% CI
Vemurafenib	47589.5	± 16667.35

S-Warfarin - AUC(0-last) (n = 20)

Group	Value	95% CI
Vemurafenib	14964.5	± 4566.80

S-Warfarin - AUC(0-inf) (n = 20)

Group	Value	95% CI
Vemurafenib	17832.5	± 6785.62

Omeprazole - AUC(0-last) (n = 20)

Group	Value	95% CI
Vemurafenib	3110.4	± 2956.30

Omeprazole - AUC(0-inf) (n = 20)

Group	Value	95% CI
Vemurafenib	3181.0	± 3107.71

AUC(0-last) and AUC(0-inf) of Probe Parent Drugs and Their Metabolites on Day 20 Primary · Day 20: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

Caffeine - AUC(0-last) (n = 19)

Group	Value	95% CI
Vemurafenib	140991.9	± 56983.62

Caffeine - AUC(0-inf) (n = 19)

Group	Value	95% CI
Vemurafenib	161490.6	± 81139.12

Paraxanthine - AUC(0-last) (n = 19)

Group	Value	95% CI
Vemurafenib	51344.3	± 14888.54

Paraxanthine - AUC(0-inf) (n = 19)

Group	Value	95% CI
Vemurafenib	55060.5	± 15481.99

S-Warfarin - AUC(0-last) (n = 20)

Group	Value	95% CI
Vemurafenib	17804.4	± 5956.35

S-Warfarin - AUC(0-inf) (n = 20)

Group	Value	95% CI
Vemurafenib	22233.3	± 9485.43

Omeprazole - AUC(0-last) (n = 20)

Group	Value	95% CI
Vemurafenib	3155.6	± 3090.03

Omeprazole - AUC(0-inf) (n = 20)

Group	Value	95% CI
Vemurafenib	3224.9	± 3200.67

Area Under the Plasma Concentration-Time Curve From Time Zero to 8, 12, and 24 Hours (AUC[0-8], AUC[0-12], AUC[0-24]) of Vemurafenib Primary · 0, 0.5, 1, 2, 4, 8, 12, 13, 14, 16, 18, 24 hours on Day 19

Area under the plasma concentration-time curve calculated using the linear trapezoidal rule from time zero to 8, 12, and 24 hours (AUC\[0-8\], AUC\[0-12\], AUC\[0-24\], respectively).

AUC(0-8)

Group	Value	95% CI
Vemurafenib	422	± 121

AUC(0-12)

Group	Value	95% CI
Vemurafenib	601	± 170

AUC(0-24)

Group	Value	95% CI
Vemurafenib	1176	± 368

Cmax of Probe Parent Drugs and Their Metabolites on Day 1 Primary · Day 1: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

Timeframe reported for parent probe drug is also applicable for their metabolite except S-warfarin as S-warfarin does not have a metabolite.

Caffeine - Cmax (n = 19)

Group	Value	95% CI
Vemurafenib	4768.9	± 1108.43

Paraxanthine - Cmax (n = 19)

Group	Value	95% CI
Vemurafenib	1839.1	± 477.75

S-Warfarin - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	469.4	± 127.22

Omeprazole - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	913.7	± 610.63

OH-Omeprazole - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	331.3	± 127.60

Dextromethorphan - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	3.38	± 4.236

Dextrorphan - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	6.49	± 5.041

Midazolam - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	41.88	± 29.197

Cmax of Probe Parent Drugs and Their Metabolites on Day 20 Primary · Day 20: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

Timeframe reported for parent probe drug is also applicable for their metabolite except S-warfarin as S-warfarin does not have a metabolite.

Caffeine - Cmax (n = 19)

Group	Value	95% CI
Vemurafenib	4990.5	± 1005.33

Paraxanthine - Cmax (n = 19)

Group	Value	95% CI
Vemurafenib	1154.9	± 446.30

S-Warfarin - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	468.3	± 115.63

Omeprazole - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	945.8	± 535.41

OH-Omeprazole - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	348.7	± 168.43

Dextromethorphan - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	4.19	± 5.342

Dextrorphan - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	7.10	± 4.332

Midazolam - Cmax (n = 20)

Group	Value	95% CI
Vemurafenib	26.18	± 13.811

Cmax of Vemurafenib Primary · 0, 0.5, 1, 2, 4, 8, 12, 13, 14, 16, 18, 24 hours on Day 19

Group	Value	95% CI
Vemurafenib	61.7	± 17.2

Time to Reach Maximum Plasma Concentration (Tmax) of Probe Parent Drugs and Their Metabolites on Day 1 Primary · Day 1: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

Timeframe reported for parent probe drug is also applicable for their metabolite except S-warfarin as S-warfarin does not have a metabolite.

Caffeine - Tmax (n = 19)

Group	Value	95% CI
Vemurafenib	1.00	1.00 – 3.00

Paraxanthine - Tmax (n = 19)

Group	Value	95% CI
Vemurafenib	8.00	4.00 – 24.00

S-Warfarin - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	3.00	1.00 – 6.00

Omeprazole - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	3.00	1.00 – 8.00

OH-Omeprazole - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	3.00	1.00 – 8.00

Dextromethorphan - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	1.50	0.50 – 3.00

Dextrorphan - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	1.50	0.50 – 4.00

Midazolam - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	0.50	0.25 – 2.00

Tmax of Probe Parent Drugs and Their Metabolites on Day 20 Primary · Day 20: 0, 1, 3, 4, 6, 8, 24 hours, additionally for caffeine 0.5, 1.5, 2, 12, 18, 48, 72, 96, 120,dextromethorphan 0.5, 1.5, 2, 12, 18, 48,midazolam 0.08, 0.25, 0.5, 0.75, 2, 10,omeprazole 0.5, 1.5, 2, 2.5, 12, 18,S-warfarin 12, 48, 72, 96, 120 hours

Timeframe reported for parent probe drug is also applicable for their metabolite except S-warfarin as S-warfarin does not have a metabolite.

Caffeine - Tmax (n = 19)

Group	Value	95% CI
Vemurafenib	2.00	1.00 – 122.00

Paraxanthine - Tmax (n = 19)

Group	Value	95% CI
Vemurafenib	24.00	8.00 – 122.00

S-Warfarin - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	3.00	1.00 – 8.00

Omeprazole - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	2.5	1.0 – 8.0

OH-Omeprazole - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	3.00	1.00 – 8.00

Dextromethorphan - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	1.50	0.50 – 3.00

Dextrorphan - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	1.50	1.00 – 3.00

Midazolam - Tmax (n = 20)

Group	Value	95% CI
Vemurafenib	0.50	0.25 – 1.05

Tmax of Vemurafenib Primary · 0, 0.5, 1, 2, 4, 8, 12, 13, 14, 16, 18, 24 hours on Day 19

Group	Value	95% CI
Vemurafenib	3.10	0.00 – 26.1

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 28 days after the last dose of study drug (median treatment duration: 144 days). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Vemurafenib

Serious: 12/25 (48%)

Deaths: —

Serious adverse events (10 terms)

Reaction	System	Vemurafenib
Squamous cell carcinoma of skin	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—
Basal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—
Keratoacanthoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—
Febrile neutropenia	Blood and lymphatic system disorders	—
Uveitis	Eye disorders	—
Gastrointestinal haemorrhage	Gastrointestinal disorders	—
Pyrexia	General disorders	—
Blood alkaline phosphatase increased	Investigations	—
Dehydration	Metabolism and nutrition disorders	—
Cerebrovasular accident	Nervous system disorders	—

Other adverse events (79 terms — click to expand)

Reaction	System	Vemurafenib
Fatigue	General disorders	—
Arthralgia	Musculoskeletal and connective tissue disorders	—
Photosensitivity reaction	Skin and subcutaneous tissue disorders	—
Hyperkeratosis	Skin and subcutaneous tissue disorders	—
Pruritus	Skin and subcutaneous tissue disorders	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—
Alopecia	Skin and subcutaneous tissue disorders	—
Nausea	Gastrointestinal disorders	—
Headache	Nervous system disorders	—
Skin papilloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—
Actinic Keratosis	Skin and subcutaneous tissue disorders	—
Diarrhoea	Gastrointestinal disorders	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—
Anaemia	Blood and lymphatic system disorders	—
Oedema peripheral	General disorders	—
Pyrexia	General disorders	—
Nipple swelling	Reproductive system and breast disorders	—
Rash	Skin and subcutaneous tissue disorders	—
Dry eye	Eye disorders	—
Vomiting	Gastrointestinal disorders	—
Chills	General disorders	—
Sunburn	Injury, poisoning and procedural complications	—
Gamma-glutamyltransferase increased	Investigations	—
Decreased appetite	Metabolism and nutrition disorders	—
Hypokalaemia	Metabolism and nutrition disorders	—
Hyponatraemia	Metabolism and nutrition disorders	—
Dysgeusia	Nervous system disorders	—
Acne	Skin and subcutaneous tissue disorders	—
Palmar-plantar erythrodysaesthesia syndrome	Skin and subcutaneous tissue disorders	—
Hypertension	Vascular disorders	—
Upper respiratory tract infection	Infections and infestations	—
Blood alkaline phosphatase increased	Investigations	—
Blood creatinine increased	Investigations	—
Weight decreased	Investigations	—
White blood cell count decreased	Investigations	—
Joint stiffness	Musculoskeletal and connective tissue disorders	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	—
Anxiety	Psychiatric disorders	—
Insomnia	Psychiatric disorders	—

Most-reported serious reactions: Squamous cell carcinoma of skin, Basal cell carcinoma, Keratoacanthoma, Febrile neutropenia, Uveitis, Gastrointestinal haemorrhage, Pyrexia, Blood alkaline phosphatase increased.

Data from ClinicalTrials.gov NCT01001299 adverse events section.

Sponsor's own description

This open-label single-arm study will evaluate the effect of RO5185426 \[RG7204; PLEXXIKON: PLX4032\] on the pharmacokinetics of five CYP450 substrates (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) administered as a drug cocktail to patients with metastatic melanoma. The study will also evaluate efficacy and safety of RO5185426. On day 1, patients will receive the drug cocktail. On days 6 to 19, patients will receive RO5185426 twice daily. On day 20, patients will receive RO5185426 and the drug cocktail and on days 21 to 25, patients will receive RO5185426. Assessments will be made at regular intervals during the dosing periods and at follow-up. Patients may continue on study treatment (RO5185426) until the development of progressive disease or unacceptable toxicity. Target sample size \<50.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Su F, Viros A, Milagre C, Trunzer K, et al · · 2012 · cited 802× · PMID 22256804 · DOI 10.1056/nejmoa1105358
Biological challenges of BRAF inhibitor therapy.
Puzanov I, Burnett P, Flaherty KT. · · 2011 · cited 28× · PMID 21393075 · DOI 10.1016/j.molonc.2011.01.005

Verify or expand the search:

Other trials of Drug cocktail

Trials testing the same drug.

NCT06693960 — Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach · EARLY_PHASE1 · recruiting

Other recruiting trials for Malignant Melanoma

Currently open trials in the same condition.

NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06961006 — A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0 · Phase 2 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01001299 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 15 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01001299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01001299

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (10 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Drug cocktail

Other recruiting trials for Malignant Melanoma

Other Hoffmann-La Roche trials

Verify against primary sources